Opioid Use Disorder
Based on current evidence, there is a strong consensus that medication-assisted treatment is recommended over detoxification in the treatment of opioid use disorder during pregnancy.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
According to the authors, this report represents the first case of recurrent fallacious lactatemia secondary to EG poisoning in the setting of drug-seeking behavior.
National Institutes of Health Director, Francis Collins, MD, PhD, announced on April 4, 2018 the launch of the Helping to End Addiction Long-Term Initiative.
Adolescents with anxiety, mood, neurodevelopmental, sleep, and nonopioid substance use disorders and most mental health treatments were significantly more likely to receive opioids.
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
Various strategies to reduce opioid overdose deaths have been implemented and it has been suggested that access to medical cannabis may lead to a reduction in opioid use for pain management.
Extended-release naltrexone and sublingual buprenorphine-naloxone were equally effective for preventing opioid abuse relapse.
Slow-Release Oral Morphine, a Promising Opioid Agonist Therapy Alternative to Buprenorphine, MethadoneJanuary 11, 2018
Slow-release oral morphine may be a valuable tool to help reduce the number of deaths from opioid-related overdose.
New guidelines were formulated for the use of urine drug monitoring in risk stratification and the prevention of opioid use disorder, overdose, and diversion.
In a press release issued November 30, 2017, the US Food and Drug Administration announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder.
Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.
A motivational interviewing intervention delivered by trained counselors reduced the rate of opioid overdoses in participants with opioid use disorder.
Patients with opioid and/or alcohol use disorders have better treatment access and greater rates of alcohol and drug abstinence at 6 months with collaborative care vs standard addiction care.
The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.
Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use DisorderJune 20, 2017
Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.
A recent study found high rates of mortality and morbidity in patients with opioid use disorder in a large healthcare system.
The researchers found that novice prescribers cited insufficient access to substance abuse counseling for patients, as well as insufficient access to more experienced prescribers, as reasons for not treating more patients.
A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.
Clinical Pain Advisor Articles
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Remission Rates and Predictors of Chronic Headache
- Overuse and Underuse of Imaging Common in Low Back Pain Management
- Unit-Dose Packaging of Buprenorphine-Naloxone Effective on Unintentional Pediatric Exposure
- Language Used in Medical Record Can Affect Patient Care
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes